PT  - JOURNAL ARTICLE
AU  - PINUCCIA FAVIANA
AU  - LAURA BOLDRINI
AU  - BARBARA MUSCO
AU  - MAURO FERRARI
AU  - ALFONSO GRECO
AU  - LORENZO FORNARO
AU  - GIANLUCA MASI
AU  - FRANCESCO FORFORI
AU  - SERGIO RICCI
AU  - AUGUSTO BROGI
AU  - FULVIO BASOLO
AU  - ALFREDO FALCONE
AU  - ANGELO GADDUCCI
AU  - PIERO VINCENZO LIPPOLIS
TI  - Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center
AID  - 10.21873/invivo.12008
DP  - 2020 Jul 01
TA  - In Vivo
PG  - 2061--2066
VI  - 34
IP  - 4
4099  - http://iv.iiarjournals.org/content/34/4/2061.short
4100  - http://iv.iiarjournals.org/content/34/4/2061.full
SO  - In Vivo2020 Jul 01; 34
AB  - Background: Peritoneal carcinomatosis (PC) is a common manifestation of many gastrointestinal (GI) malignancies and is an advanced stage that is often associated with disseminated disease. Considerable progress has been made to achieve safe elimination of macroscopic disease using cytoreductive surgery (CRS) and more recently in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of microscopic disease or disease with minimal volume. The aim of this study was to assess the effects of such procedures on the quality of life (QoL), the long-term benefit and the functional status of the treated patients. Patients and Methods: Data from patients who underwent CRS-HIPEC for peritoneal metastasis (PM) at our center from November 2016 to November 2018 were analyzed retrospectively. The drugs administered were mitomycin and cisplatin. Quality of life (QoL) was assessed using the Euroquol-5D-5L and National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index v2 questionnaires before CRS-HIPEC, and 1, 3 and 6 months after were administered. Results: In our series, the survival efficacy of CRS plus HIPEC was confirmed in the treatment of primary and secondary peritoneal pathologies, particularly in ovarian cancer, although larger studies are needed to investigate its role in the pathology of gastric, colonic and rectal cancer. The QoL data were promising, with essentially stable values between the preoperative and the 1-month follow-up, but with incremental benefits from the second to the third month.